[Results of application of CS-1170 to pediatric infections (author's transl)]

Insights

CS-1170 demonstrated effectiveness in all 11 infection cases, including respiratory and urinary tract infections. This new antibiotic shows promise, especially against resistant E. coli, with no observed side effects.

Area of Science:

  • Pharmacology and Infectious Diseases

Context:

  • CS-1170 is an antibiotic investigated for treating bacterial infections.
  • Previous treatments showed limitations against certain resistant bacterial strains.

Purpose:

  • To evaluate the clinical efficacy and safety of CS-1170 in patients with various bacterial infections.

Summary:

  • CS-1170 was administered to 11 patients with respiratory infections, urinary-tract infections, and subacute bacterial endocarditis.
  • The drug was effective in all cases, with notable success in bronchopneumonia and two E. coli urinary-tract infections resistant to other antibiotics.
  • CS-1170 exhibited strong activity against beta-lactamase-producing bacteria, including ampicillin- and cefazolin-resistant E. coli.

Impact:

  • The findings highlight CS-1170's clinical significance and utility, particularly for infections caused by multidrug-resistant bacteria.
  • The absence of observed side effects suggests a favorable safety profile for CS-1170.